Irsamla (Vortioxetine Hydrobromide)

Vortioxetine blocks the reuptake of serotonin and modulates several serotonin receptors—acting as a 5‑HT1A agonist, 5‑HT1B partial agonist, and antagonizing 5‑HT3 and 5‑HT7 receptors. This multifaceted activity increases serotonin signaling and contributes to its antidepressant effect.

The specific dose of Irsamla is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety data for vortioxetine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To order Irsamla, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Irsamla (vortioxetine) differs from many traditional SSRIs by also modulating multiple serotonin receptors, which may improve cognitive symptoms in depression. Its side‑effect profile can be distinct, with lower rates of sexual dysfunction for some patients, but individual response varies, making a clinician‑guided comparison essential.

Irsamla should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme heat to maintain its stability and potency throughout its shelf life.

Irsamla is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with water; do not crush or chew unless specifically instructed by a healthcare professional.

The most serious risks include the emergence of suicidal thoughts or behaviors, especially in younger adults, and serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored closely for mood changes, agitation, fever, or neuromuscular abnormalities.

Irsamla should not be used by individuals who are currently taking monoamine oxidase inhibitors, have a known hypersensitivity to vortioxetine or any excipients, or have a history of severe serotonin syndrome. Caution is also advised for patients with uncontrolled hypertension or significant hepatic impairment.